A Case of Bowen's Disease During Adalimumab Treatment for Felty's Syndrome.
- Author:
Ha Yeol PARK
1
;
Hyun Sook KIM
;
Ran HONG
Author Information
1. Department of Internal Medicine, College of Medicine, Chosun University, Gwangju, Korea. healthyra@chosun.ac.kr
- Publication Type:Case Report
- Keywords:
Anti-tumor necrosis factor agent;
Bowen's disease;
Felty's syndrome
- MeSH:
Antibodies, Monoclonal, Humanized;
Antirheumatic Agents;
Arsenic;
Arthritis, Rheumatoid;
Bowen's Disease;
Carcinoma, Squamous Cell;
Eating;
Felty Syndrome;
Female;
Humans;
Immunosuppression;
Middle Aged;
Necrosis;
Neutropenia;
Papilloma;
Skin;
Skin Neoplasms;
Solar System;
Splenomegaly;
Viruses;
Adalimumab
- From:Korean Journal of Medicine
2012;83(3):400-404
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Felty's syndrome is an uncommon condition characterized by the combination of rheumatoid arthritis (RA), splenomegaly, and neutropenia. Disease-modifying anti-rheumatic drugs and biologic agents have been used to treat early RA to achieve remission. Anti-tumor necrosis factor (TNF)-alpha agents are effective for controlling the disease; however, some studies have suggested the possibility of adverse effects such as increased frequency of infection or malignancy. Bowen's disease, known as squamous cell carcinoma in situ, is a skin cancer that can be caused by sun exposure, arsenic ingestion, human papilloma virus, skin damage, and prolonged immunosuppression. We report the case of a 64-year-old female diagnosed with Bowen's disease during treatment with an anti-TNF agent for Felty's syndrome with a review of the literature.
